cytochrome P450 family 26 subfamily A member 1Genealiases: CP26 · CYP26 · P450RAI · P450RAI1
Q-omics provides the consensus-scored CYP26A1 profile across patient tissues and cancer cell-line models. CYP26A1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CYP26A1 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, CYP26A1 RNA expression shows 14,176 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, LIHC, and TGCT as cancer lineages where CYP26A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP26A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP26A1 survival associations across molecular data types. CYP26A1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP26A1 RNA expression–survival associations across cancer types. High CYP26A1 expression shows unfavorable associations in KIRC, ACC, KIRP and STAD, but favorable associations in CESC and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CYP26A1 RNA expression.
This table summarizes CYP26A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for CYP26A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP26A1 shows lower tumor expression in LIHC and higher tumor expression in COAD, THCA, LUAD, HNSC and UCEC. The LIHC box plot shows higher CYP26A1 RNA expression in normal versus tumor tissue (log2 FC = −2.664, t-test p < 0.001).
This table shows molecular features associated with CYP26A1 in patient tissues and cancer cell lines. In patient samples, CYP26A1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CYP26A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BONE and SOFT_TISSUE.
